D'Agnano I, D'Angelo C, Savarese A, Carlini M, Garofalo A, Bottari L, Santoro E, Giannarelli D, Vecchione A, Zupi G
Laboratory Experimental Chemotherapy, CRS, Rome, Italy.
Lab Invest. 1995 Apr;72(4):432-8.
The 5-year survival rate of patients with stomach cancer is usually around 20%. The clinico-pathological features that are presently used to assess patient prognosis are not sufficient to define gastric tumor behavior. Therefore, an accurate analysis of different biological characteristics of gastric cancer cells could allow the course of disease to be predicted and may help to improve treatment strategies.
The prognostic values of DNA ploidy, proliferative activity and epidermal growth factor receptor (EGF-R) expression were studied in gastric tumors from a series of 63 patients. DNA ploidy and proliferative activity, evaluated in terms of DNA index (DI) and proliferative index (PI), respectively, were determined by flow cytometry on paraffin-embedded tumor tissues. EGF-R expression was detected by immunohistochemistry on paraffin-embedded tumor sections of the same specimens. The clinico-pathological and the biological parameters were then correlated, and the patients overall survival was calculated using a chi-square test and the Kaplan-Meier method.
DNA ploidy abnormal cell clones were found in 44% of cases (median DI = 1.4, range 1.04-2.5). Aneuploid tumors showed high PI more frequently than diploids (71% versus 36%, p = 0.01). The analysis of the expression of EGF-R revealed that 88% of aneuploid tumors were positive for receptor expression. On the contrary, diploid tumors showed the presence of EGF-R only in 56% of cases (p = 0.01). DI, PI, and EGF-R expression were not related to histological grade. Conversely, the three biological parameters were significantly correlated to clinical stage and tumor invasion. The Kaplan-Meier survival curves showed a 73% 5-year survival rate in patients with diploid tumors whereas only 33% of patients with aneuploid lesions had a good prognosis (p = 0.001).
We demonstrate that DNA ploidy, PI, and EGF-R expression are closely related to some pathological and clinical characteristics in gastric cancer. The close relationship between aneuploidy, EGF-R positive expression, node involvement, and tumor invasion suggests that these parameters may be indicators of high malignancy. Finally, the results also show that aneuploidy and EGF-R-positive expression are indicative of a worse prognosis in gastric cancer patients. The study of these parameters might allow a more accurate stratification of patients, so that a targeted therapeutic protocol may be defined.
胃癌患者的5年生存率通常约为20%。目前用于评估患者预后的临床病理特征不足以界定胃肿瘤的行为。因此,准确分析胃癌细胞的不同生物学特性可以预测疾病进程,并可能有助于改进治疗策略。
研究了63例患者胃肿瘤中DNA倍体、增殖活性和表皮生长因子受体(EGF-R)表达的预后价值。DNA倍体和增殖活性分别根据DNA指数(DI)和增殖指数(PI)进行评估,通过对石蜡包埋肿瘤组织进行流式细胞术测定。EGF-R表达通过对相同标本的石蜡包埋肿瘤切片进行免疫组织化学检测。然后将临床病理参数与生物学参数进行关联,并使用卡方检验和Kaplan-Meier方法计算患者的总生存率。
44%的病例中发现了DNA倍体异常细胞克隆(中位DI = 1.4,范围1.04 - 2.5)。非整倍体肿瘤比二倍体肿瘤更频繁地显示高PI(71%对36%,p = 0.01)。对EGF-R表达的分析显示,88%的非整倍体肿瘤受体表达呈阳性。相反,二倍体肿瘤仅在56%的病例中显示EGF-R存在(p = 0.01)。DI、PI和EGF-R表达与组织学分级无关。相反,这三个生物学参数与临床分期和肿瘤侵袭显著相关。Kaplan-Meier生存曲线显示,二倍体肿瘤患者的5年生存率为73%,而非整倍体病变患者只有33%预后良好(p = 0.001)。
我们证明DNA倍体、PI和EGF-R表达与胃癌的一些病理和临床特征密切相关。非整倍体、EGF-R阳性表达、淋巴结受累和肿瘤侵袭之间的密切关系表明这些参数可能是高恶性的指标。最后,结果还表明非整倍体和EGF-R阳性表达表明胃癌患者预后较差。对这些参数的研究可能使患者分层更准确,从而可以确定有针对性的治疗方案。